8-K: Boston Scientific Completes $3.7 Billion Acquisition of Axonics, Inc.

Boston Scientific has finalized its acquisition of Axonics, Inc., a medical technology company specializing in devices for urinary and bowel dysfunction, for $3.7 billion.

Summary

• Boston Scientific completed the acquisition of Axonics, Inc. on November 15, 2024.
• The purchase price was $71 per share in cash, representing an equity value of $3.7 billion.
• The enterprise value of the deal is $3.3 billion, net of cash and short-term investments acquired.
• The transaction is expected to be immaterial to Boston Scientific's adjusted earnings per share in 2024 and 2025.
• The acquisition is expected to become accretive to adjusted earnings per share after 2025.
• On a GAAP basis, the transaction is expected to be less accretive or more dilutive due to amortization expense and acquisition-related charges.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the strategic acquisition and expected future accretion, but tempered by the near-term immaterial impact on earnings and potential integration risks.

Positives

• The acquisition allows Boston Scientific to expand into the high-growth sacral neuromodulation market.
• The deal is expected to be accretive to adjusted earnings per share after 2025.
• Axonics' product portfolio will provide a comprehensive range of treatment options for patients with urinary and bowel dysfunction.
• The acquisition brings innovative technologies to Boston Scientific's portfolio.

Negatives

• The transaction is expected to be less accretive or more dilutive on a GAAP basis due to amortization and acquisition-related charges.
• The acquisition is expected to be immaterial to adjusted earnings per share in 2024 and 2025.

Risks

• The integration of Axonics' operations may present challenges.
• There are risks associated with achieving the anticipated benefits of the transaction.
• Future economic, political, competitive, reimbursement and regulatory conditions could impact the success of the acquisition.
• Geopolitical events, supply chain disruptions, and cybersecurity events could also affect the company.
• Variations in clinical trial outcomes and market studies could impact the performance of the acquired products.

Future Outlook

The acquisition is expected to be immaterial to adjusted earnings per share in 2024 and 2025 and accretive thereafter, with less accretion or more dilution expected on a GAAP basis due to amortization and acquisition-related charges.

Management Comments

• Meghan Scanlon, senior vice president and president, Urology, Boston Scientific, stated that Axonics has delivered meaningful innovations for patients with overactive bladder and incontinence.
• Meghan Scanlon also mentioned that the acquisition allows Boston Scientific to expand into sacral neuromodulation.

Industry Context

This acquisition reflects a trend in the medical device industry towards consolidation and expansion into high-growth adjacencies, with Boston Scientific leveraging the acquisition to strengthen its position in the urology market and expand into sacral neuromodulation.

Comparison to Industry Standards

• The acquisition of Axonics by Boston Scientific is comparable to other strategic acquisitions in the medical device industry, where larger companies acquire smaller, innovative firms to expand their product portfolios and market reach.
• For example, Medtronic's acquisition of Mazor Robotics in 2018 for $1.7 billion is a similar example of a large medical device company acquiring a smaller company with innovative technology.
• The $3.7 billion price tag for Axonics is within the range of other acquisitions of medical device companies with similar growth potential and market position.
• The focus on sacral neuromodulation aligns with the industry's increasing interest in minimally invasive treatments for chronic conditions.

Stakeholder Impact

• Shareholders of Boston Scientific may see long-term value creation from the acquisition.
• Employees of Axonics will become part of Boston Scientific.
• Patients will have access to a broader range of treatment options for urinary and bowel dysfunction.
• The acquisition may impact suppliers and customers of both companies.

Next Steps

• Boston Scientific will integrate Axonics' operations into its existing business.
• The company will work to achieve the anticipated benefits of the transaction.
• Boston Scientific will continue to monitor the financial impact of the acquisition.

Key Dates

Keywords

acquisition, medical technology, neuromodulation, urinary dysfunction, bowel dysfunction, Boston Scientific, Axonics, merger, healthcare, incontinence